Editorial: Should we use SSRIs in pregnancy?

Article

Chambers and colleagues observed a 6.1-fold increased risk of persistent pulmonary hypertension in newborns whose mothers had received SSRIs after 20 weeks' gestation.

Between 3.1% and 4.9% of women experience major depression during pregnancy, and up to 15% of pregnant women have clinical depression of some sort.1 Left untreated, 50% of women who are depressed during pregnancy will experience a postpartum exacerbation, which itself carries a 15% risk of attempted suicide.2 Besides the psychological anguish a depressed mother feels, evidence suggests that if her condition goes untreated, her fetus may be at increased risk of prematurity, fetal growth restriction, stillbirth, and low Apgar scores.2

Psychotherapy appears to work well in the treatment of depressed patients, with one randomized clinical trial suggesting a 60% remission rate compared to 15.4% in a parenting education control group.3 Such therapy also appears to improve maternal-infant bonding. Unfortunately, the availability of practitioners trained in validated therapies for depression is quite limited, insurance coverage is frequently unavailable, and out-of-pocket expense can be significant. So, ob/gyns and mental health providers have increasingly turned to SSRIs to treat depressed pregnant patients. In general, these drugs have few side effects, are well tolerated and easy to administer, have high compliance rates, and are more effective than tricyclic antidepressants and monoamine oxidase (MAO) inhibitors. Initial reports suggested that SSRIs were safe and effective in pregnancy, with no discernable increased risk of adverse neonatal effects or teratogenicity.4

These reports seem to suggest that pregnant women should not be treated with SSRIs. But they must be balanced against another very recent report of a nearly 70% risk of relapse among previously depressed pregnant women after discontinuing antidepressants-chiefly SSRIs (see also Clinical Insights).6

Related Videos
The significance of the Supreme Court upholding mifepristone access | Image Credit: unchealth.org
One year out: Fezolinetant displays patient satisfaction for managing hot flashes | Image Credit: sutterhealth.org
Addressing maternal health inequities: Insights from CDC's Wanda Barfield | Image Credit: cdc.gov
Addressing racial and ethnic disparities in brachial plexus birth Injury | Image Credit: shrinerschildrens.org
Innovations in prenatal care: Insights from ACOG 2024 | Image Credit:  uofmhealth.org.
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit: uclahealth.org.
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit: mayo.edu.
raanan meyer, md
Related Content
© 2024 MJH Life Sciences

All rights reserved.